Compare GLU & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | RPTX |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | GLU | RPTX |
|---|---|---|
| Price | $18.38 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 12.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.61 | $0.89 |
| 52 Week High | $15.40 | $4.07 |
| Indicator | GLU | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 60.62 |
| Support Level | $18.25 | $2.11 |
| Resistance Level | $18.60 | $2.24 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 55.04 | 40.91 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.